{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2025,6,3]],"date-time":"2025-06-03T17:40:10Z","timestamp":1748972410630,"version":"3.41.0"},"reference-count":14,"publisher":"Ovid Technologies (Wolters Kluwer Health)","issue":"4","content-domain":{"domain":["lww.com","ovid.com"],"crossmark-restriction":true},"short-container-title":[],"published-print":{"date-parts":[[2023,8]]},"abstract":"<jats:sec>\n            <jats:title>Background:<\/jats:title>\n            <jats:p>A patient, with a mental disorder caused by an intracranial infection, treated with olanzapine, fluvoxamine, and buspirone. The plasma exposure of olanzapine was too high at standard doses, with evidence indicating that it was caused by drug\u2013drug interactions.<\/jats:p>\n          <\/jats:sec>\n          <jats:sec>\n            <jats:title>Methods:<\/jats:title>\n            <jats:p>Using pharmacogenomics and therapeutic drug monitoring to guide drug dose adjustment for a patient in clinical practice.<\/jats:p>\n          <\/jats:sec>\n          <jats:sec>\n            <jats:title>Results:<\/jats:title>\n            <jats:p>The patient underwent pharmacogenetic testing in addition to therapeutic drug monitoring as part of a pharmacist-led comprehensive evaluation of medication therapy management in a clinical setting, resulting in improved clinical efficacy that allowed discharge from a psychiatric hospital.<\/jats:p>\n          <\/jats:sec>\n          <jats:sec>\n            <jats:title>Conclusions:<\/jats:title>\n            <jats:p>This case study demonstrates that therapeutic drug monitoring combined with pharmacogenetic-guided dose adjustment can aid in the management of patients receiving complex pharmacological treatments.<\/jats:p>\n          <\/jats:sec>","DOI":"10.1097\/ftd.0000000000001093","type":"journal-article","created":{"date-parts":[[2023,3,14]],"date-time":"2023-03-14T20:07:19Z","timestamp":1678824439000},"page":"425-427","update-policy":"https:\/\/doi.org\/10.1097\/lww.0000000000001000","source":"Crossref","is-referenced-by-count":1,"title":["Usefulness of Therapeutic Drug Monitoring and Pharmacogenetics for a Patient Treated with Olanzapine, Buspirone, and Fluvoxamine: A Case Study"],"prefix":"10.1097","volume":"45","author":[{"given":"Jing","family":"Ding","sequence":"first","affiliation":[{"name":"Pharmacy Laboratory, Xi'an Mental Health Center, Xi'an, P.R. China;"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Liu","family":"Yang","sequence":"additional","affiliation":[{"name":"Science and Education Department, Xi'an Mental Health Center, Xi'an, P.R. China; and"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Yan","family":"Zhang","sequence":"additional","affiliation":[{"name":"Pharmacy Laboratory, Xi'an Mental Health Center, Xi'an, P.R. China;"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Zhuocheng","family":"Meng","sequence":"additional","affiliation":[{"name":"Pharmacy Laboratory, Xi'an Mental Health Center, Xi'an, P.R. China;"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Jianli","family":"Ren","sequence":"additional","affiliation":[{"name":"Psychiatry Department, Xi'an Mental Health Center, Xi'an, P.R. China."}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Suo","family":"Zhang","sequence":"additional","affiliation":[{"name":"Pharmacy Laboratory, Xi'an Mental Health Center, Xi'an, P.R. China;"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Jiarui","family":"Liu","sequence":"additional","affiliation":[{"name":"Psychiatry Department, Xi'an Mental Health Center, Xi'an, P.R. China."}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Xiaohua","family":"Cui","sequence":"additional","affiliation":[{"name":"Pharmacy Laboratory, Xi'an Mental Health Center, Xi'an, P.R. China;"}],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"276","published-online":{"date-parts":[[2023,3,14]]},"reference":[{"key":"R1-20250603","doi-asserted-by":"crossref","first-page":"368","DOI":"10.4088\/JCP.v68n0303","article-title":"A randomized controlled trial of olanzapine versus haloperidol in the treatment of primary negative symptoms and neurocognitive deficits in schizophrenia","volume":"68","author":"Lindenmayer","year":"2007","journal-title":"J Clin Psychiatry"},{"key":"R2-20250603","doi-asserted-by":"crossref","first-page":"803","DOI":"10.1016\/S0006-3223(98)00093-6","article-title":"A double-blind, controlled comparison of the novel antipsychotic olanzapine versus haloperidol or placebo on anxious and depressive symptoms accompanying schizophrenia","volume":"43","author":"Tollefson","year":"1998","journal-title":"Biol Psychiatry"},{"key":"R3-20250603","doi-asserted-by":"crossref","first-page":"247","DOI":"10.1176\/appi.ajp.163.2.247","article-title":"Randomized, placebo-controlled trial of olanzapine as maintenance therapy in patients with bipolar I disorder responding to acute treatment with olanzapine","volume":"163","author":"Tohen","year":"2006","journal-title":"Am J Psychiatry"},{"key":"R4-20250603","first-page":"81","article-title":"Disposition and biotransformation of the antipsychotic agent olanzapine in humans","volume":"25","author":"Kassahun","year":"1997","journal-title":"Drug Metab Dispos."},{"key":"R5-20250603","doi-asserted-by":"crossref","first-page":"658","DOI":"10.1016\/S0022-3565(25)12326-4","article-title":"Identification of the human cytochromes P450 responsible for the in vitro formation of the major oxidative metabolites of the antipsychotic agent olanzapine","volume":"276","author":"Ring","year":"1996","journal-title":"J Pharmacol Exp Ther."},{"key":"R6-20250603","doi-asserted-by":"crossref","first-page":"410","DOI":"10.2174\/138920008784746373","article-title":"Metabolism of atypical antipsychotics: involvement of cytochrome p450 enzymes and relevance for drug-drug interactions","volume":"9","author":"Urichuk","year":"2008","journal-title":"Curr Drug Metab."},{"key":"R7-20250603","doi-asserted-by":"crossref","first-page":"410","DOI":"10.1097\/00007691-200108000-00015","article-title":"Fluvoxamine but not sertraline inhibits the metabolism of olanzapine: evidence from a therapeutic drug monitoring service","volume":"23","author":"Weigmann","year":"2001","journal-title":"Ther Drug Monit."},{"key":"R8-20250603","doi-asserted-by":"crossref","first-page":"502","DOI":"10.1097\/00004714-200210000-00010","article-title":"Fluvoxamine augmentation of olanzapine in chronic schizophrenia: pharmacokinetic interactions and clinical effects","volume":"22","author":"Hiemke","year":"2002","journal-title":"J Clin Psychopharmacol."},{"key":"R9-20250603","doi-asserted-by":"crossref","first-page":"257","DOI":"10.1016\/S0009-9236(98)90174-6","article-title":"Effect of fluvoxamine therapy on the activities of CYP1A2, CYP2D6, and CYP3A as determined by phenotyping","volume":"64","author":"Kashuba","year":"1998","journal-title":"Clin Pharmacol Ther."},{"key":"R10-20250603","doi-asserted-by":"crossref","first-page":"228","DOI":"10.1097\/00131746-200305000-00006","article-title":"Reproducibility of the in vivo effect of the selective serotonin reuptake inhibitors on the in vivo function of cytochrome P450 2D6: an update (part II)","volume":"9","author":"Preskorn","year":"2003","journal-title":"J Psychiatr Pract."},{"key":"R11-20250603","doi-asserted-by":"crossref","first-page":"636","DOI":"10.1097\/FTD.0000000000000738","article-title":"A retrospective analysis of steady-state olanzapine concentrations in Chinese patients using therapeutic drug monitoring: effects of valproate and other factors","volume":"42","author":"Deng","year":"2020","journal-title":"Ther Drug Monit."},{"key":"R12-20250603","doi-asserted-by":"crossref","first-page":"443","DOI":"10.1007\/s00213-003-1430-1","article-title":"Relationship between clinical effects of fluvoxamine and the steady-state plasma concentrations of fluvoxamine and its major metabolite fluvoxamino acid in Japanese depressed patients","volume":"167","author":"Gerstenberg","year":"2003","journal-title":"Psychopharmacology"},{"key":"R13-20250603","doi-asserted-by":"crossref","first-page":"9","DOI":"10.1055\/s-0043-116492","article-title":"Consensus guidelines for therapeutic drug monitoring in neuropsychopharmacology: update 2017","volume":"51","author":"Hiemke","year":"2018","journal-title":"Pharmacopsychiatry"},{"key":"R14-20250603","doi-asserted-by":"crossref","first-page":"343","DOI":"10.1038\/nature15817","article-title":"Pharmacogenomics in the clinic","volume":"526","author":"Relling","year":"2015","journal-title":"Nature"}],"container-title":["Therapeutic Drug Monitoring"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/journals.lww.com\/10.1097\/FTD.0000000000001093","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,6,3]],"date-time":"2025-06-03T17:16:17Z","timestamp":1748970977000},"score":1,"resource":{"primary":{"URL":"https:\/\/journals.lww.com\/10.1097\/FTD.0000000000001093"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2023,3,14]]},"references-count":14,"journal-issue":{"issue":"4","published-print":{"date-parts":[[2023]]}},"URL":"https:\/\/doi.org\/10.1097\/ftd.0000000000001093","relation":{},"ISSN":["0163-4356"],"issn-type":[{"type":"print","value":"0163-4356"}],"subject":[],"published":{"date-parts":[[2023,3,14]]},"assertion":[{"value":"2022-09-27","name":"received","label":"Received","group":{"name":"publication_history","label":"Publication History"}},{"value":"2022-11-30","name":"accepted","label":"Accepted","group":{"name":"publication_history","label":"Publication History"}}]}}